Medtronic 2011 Annual Report Download - page 29

Download and view the complete annual report

Please find page 29 of the 2011 Medtronic annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 106

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83
  • 84
  • 85
  • 86
  • 87
  • 88
  • 89
  • 90
  • 91
  • 92
  • 93
  • 94
  • 95
  • 96
  • 97
  • 98
  • 99
  • 100
  • 101
  • 102
  • 103
  • 104
  • 105
  • 106

25
Medtronic, Inc.
• Future growth from the launch of the Arctic Front system in
the U.S. The Arctic Front system is a cryoballoon indicated for
the treatment of drug refractory paroxysmal atrial fibrillation.
The cryoballoon treatment involves a minimally invasive
procedure that efficiently creates circumferential lesions around
the pulmonary vein, which is the source of erratic electrical
signals that cause irregular heartbeat.
• C
in markets outside the U.S.
• Launch of the new Integrity bare metal stent and Resolut e
Integrity drug eluting coronary stent in certain international
markets. The Integrity platform features a laser-fused
sinusoidal technology that is designed to significantly
improve flexibility and conformability compared to the Driver
stent and other technologies. Additionally, the Resolute
Integrity drug eluting coronary stent was launched in Europe
in August 2010. While the global stent market continues
to experience year-over-year declines, to date we have been
successful in gaining share with this stent platform in those
geographies where the product has been approved.
• Future growth in the U.S. from the launch of the Endurant
Abdominal Stent Graft System, which was approved and
launched in the third quarter of fiscal year 2011. Early results
indicate strong market acceptance.
• Further and future growth in the U.S. and Japan from the
Talent Thoracic Stent Graft System. In the U.S., the Talent
Thoracic Stent Graft System, on an improved delivery system,
Captivia, was launched in the third quarter of fiscal year
2011. In addition, our Talent Abdominal Aortic Aneurysm
Stent Graft System and improved delivery system, Xcelerant,
for our Thoracic Stent Graft System was approved in Japan in
the third quarter of fiscal year 2011.
• Sales growth outside the U.S. with continued acceptance of
our next generation Endurant Abdominal Stent Graft System
and our Valiant Captivia Thoracic Stent Graft System. Valiant
Captivia Thoracic Stent Graft System received CE Mark
approval and was commercially launched in the second
quarter of fiscal year 2010.
• Continued acceptance of our CoreValve transcatheter heart
valve technologies for the replacement of the aortic valve.
CoreValve’s Percutaneous Revalving System has received CE
Mark approval and is currently available outside the U.S.
Additionally, during the third quarter of fiscal year 2011 we
started the CoreValve U.S. pivotal study.
• Continued contributions from Invatec and its affiliated
companies into our CardioVascular business. We acquired
Invatec and its affiliated companies in the fourth quarter of
fiscal year 2010. Invatec is a developer of innovative medical
technologies for interventional treatment of cardiovascular
disease. We believe this acquisition has increased our
competitive position in the peripheral vascular market.
• Continued integration of ATS Medical, which was acquired in
the second quarter of fiscal year 2011. ATS Medical is a leading
developer, manufacturer, and marketer of products and
services focused on cardiac surgery, including heart valves
and surgical cryoablation technology. We believe this
acquisition should increase our competitive position in the
structural heart market.
• Continued integration of Ardian, Inc. (Ardian), which was
acquired near the end of the third quarter of fiscal year
2011. Ardian develops catheter-based therapies to treat
uncontrolled hypertension and related conditions. Ardian’s
Symplicity Catheter System addresses uncontrolled
hypertension through renal denervation, or ablation of the
nerves lining the renal arteries. It has received CE Mark
approval and Australia’s Therapeutic Goods Administration
listing. We believe this acquisition offers the opportunity
to lead the development of renal denervation, augments
our existing interventional therapies, and complements our
catheter design and ablation technologies.
• Future divestiture of Physio-Control. In February 2011, we
announced our intention to reinitiate our efforts to divest
Physio-Control. We are pursuing a dual-path strategy,
investigating both the option of an asset sale and the option
to spin off the business to our shareholders.
Restorative Therapies Group The Restorative Therapies Group is
composed of the Spinal, Neuromodulation, Diabetes, and Surgical
Technologies businesses. Products in the Restorative Therapies
Group include products for various areas of the spine, bone graft
therapies and drug delivery devices for the treatment of chronic
pain, movement disorders, obsessive-compulsive disorder (OCD),
overactive bladder, urinary retention, and gastroparesis, external
insulin pumps, subcutaneous continuous glucose monitoring
(CGM) systems, and products to treat conditions of the ear, nose,
and throat. Additionally, this group manufactures and sells
primarily image-guided surgery and intra-operative imaging
systems. The Restorative Therapies Group net sales for fiscal year